Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned ...

The RSI can be a tricky indicator. When it's below 30, it suggests an "oversold" condition, which, over the short-term, might suggest a bounce is due. And when it's above the "overbought" threshold of ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

Trump said he'd 'rather not' impose tariffs on China — a softening in stance that eased some fears over the potential for a trade war.

Business quiz! Shares of Meta Platforms touched a record high this week after: a) its megabillionaire chief executive Mark ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...